Physician profile
Nichole K Vanells
NPI 1952659377
$9,577.89
in general payments reported to CMS, 2019-2025
28 companies · $1,091 in 2025
The $1,091 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $84.78 · 2022: $2,300 · 2023: $2,143 · 2024: $3,960 · 2025: $1,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,625 · Food and Beverage: $2,191 · Travel and Lodging: $1,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,625.00 |
| Food and Beverage | $2,191.47 |
| Travel and Lodging | $1,377.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $7,679.32 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Biogen, INC. | $208.80 | 2023-2025 | Tysabri, Vumerity, Skyclarys |
| Abbvie INC. | $184.70 | 2021-2024 | |
| Genentech USA, INC. | $175.11 | 2023-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $153.93 | 2023-2025 | Ultomiris, Soliris, Koselugo |
| Vanda Pharmaceuticals INC. | $140.07 | 2024-2025 | Ponvory |
| Takeda Pharmaceuticals U.S.A., INC. | $126.03 | 2025 | Hyqvia |
| Jazz Pharmaceuticals INC. | $120.58 | 2022-2025 | |
| Ucb, INC. | $120.48 | 2023-2025 | Rystiggo, Nayzilam, Kygevvi |
| Sk Life Science, INC. | $99.51 | 2022-2023 | |
| Pfizer INC. | $86.75 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $63.65 | 2025 | Onpattro |
| Tanabe Pharma America, INC. | $53.48 | 2024-2025 | Radicava |
| Novo Nordisk INC | $47.92 | 2023 | Wegovy |
| Hospira, INC. | $38.06 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $35.16 | 2024 | Hizentra |
| Lundbeck LLC | $29.12 | 2025 | Vyepti |
| Eisai INC. | $26.57 | 2025 | |
| Janssen Biotech, INC. | $26.22 | 2025 | |
| Acorda Therapeutics, INC | $25.82 | 2024 | Inbrija |
| Xeris Pharmaceuticals, INC. | $24.81 | 2025 | Keveyis |
| Lilly USA, LLC | $17.98 | 2023 | Amyvid |
| Averitas Pharma INC. | $16.58 | 2025 | Qutenza |
| Avion Pharmaceuticals | $16.43 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.39 | 2025 | Rexulti |
| Amgen INC. | $15.99 | 2021 | |
| Axonics, INC. | $15.23 | 2021 | |
| Neurocrine Biosciences, INC. | $13.20 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nichole Vanells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.